Category Archives: Data Exclusivity

MSF response on RCEP negotiations in the Philippines

Source: MSF Access Campaign New Delhi, 8 May 2017 – The Philippines is set to host the 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement’s negotiations in Manila this week. Negotiators from the ten members of the … Continue reading

Posted in Data Exclusivity, Evergreening, Investor state dispute, IPR Enforcement, ISDS, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized, WTO | Leave a comment

The expanding universe of IP

Source: The Hindu Granting data exclusivity for clinical trials would undermine access to medicines April 26 is World Intellectual Property (IP) day. Over the years, global IP standards have steadily expanded beyond World Trade Organisation (WTO) requirements, thanks to free … Continue reading

Posted in Data Exclusivity, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Switzerland wants stricter intellectual property rules in India that could harm generic drug makers

By Jyotsna Singh, Scroll | March 23, 2017 Developed countries continue to put pressure on India to move to stricter intellectual property regimes that would favour multinational pharmaceutical countries over generic drug manufacturers. A new leaked document shows that the … Continue reading

Posted in Data Exclusivity, EFTA-India FTA, Evergreening, Patent, Uncategorized | Leave a comment

European FTA pushes for tougher IPR rules under ongoing trade talks with India

Switzerland proposed that India agree to broader patentable principles, as per a leaked note on the proposed Intellectual Property Rights chapter of the talks   The leaked note followed a telephone conversation commerce minister Sitharaman and Swiss minister for economic … Continue reading

Posted in Data Exclusivity, EFTA-India FTA, Evergreening, IPR, Patent, Uncategorized | Leave a comment

India–EFTA trade talks may make medicines more expensive

MSF and civil society urge Swiss negotiators not to undermine the ‘pharmacy of the developing world’   Geneva/New Delhi, 22March 2017 – Asintellectual property (IP) negotiators from India andthe four countries from EFTA (European Free Trade Association) meeting New Delhi … Continue reading

Posted in Data Exclusivity, EFTA-India FTA, Evergreening, Patent, Sec 3 (d), Uncategorized | Leave a comment

Avoid Patent Clauses in Trade Treaties that can Kill Millions

By Martin Khor, Inter Press Service | February 27, 2017 PENANG, Feb 27 2017 (IPS) – Recently a very interesting article on why there are inequalities in access to health care and how  medicine prices are beyond the reach of many … Continue reading

Posted in Data Exclusivity, FTA, Patent Term Extension, TPP, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

RCEP and Health: This Kind of ‘Progress’ is Not What India and the World Need

Source: The Wire Concerns remain over the impact of RCEP negotiations on public health and access to medicines Negotiators from 16 countries are meeting in Kobe, Japan on Monday to begin the 17th round of negotiations of the Regional Comprehensive Economic … Continue reading

Posted in Data Exclusivity, Investor state dispute, IPR, Patent, Patent Term Extension, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment